Crohn’s disease clinical trial – Now enrolling

Qu Biologics is now recruiting Canadian residents to participate in the first stage of a Phase 2 clinical trial of QBECO SSI in the treatment of adults living with moderate to severe Crohn’s disease.

The aim of this trial is to further establish the safety and efficacy of the investigational drug QBECO SSI for the induction of clinical and endoscopic response and remission. QBECO SSI is intended to restore innate immune function and achieve sustained remission off all medications. In addition, this study will help to determine whether improvement in endoscopic healing is seen after 16 weeks or after 26 weeks of treatment. See more at www.restoretrial.ca

Past events:


Past events: